Solid Cancer Clinical Trial
Official title:
Study of the Immunological Profile of Archival Formalin-fixed Paraffin-embedded Solid Tumors Sample
It has become clear in the recent year that the nature of the immune cells infiltrate within
a tumor was essential in the control of the tumor growth. This so-called immune contexture
does vary between cancer types and in response to treatments. In this context, this trial is
a non-interventional, mono-centric in patients with solid tumors. Samples in
paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or
metastases) will be analysed. For each sample, clinically relevant data associated with
treated cancer and needed for characterization of tumor microenvironment will be documented.
This trial is, through accessing to well documented selected archival tumor materials, to
validate selected biomarker for early phase trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03721679 -
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Completed |
NCT00925743 -
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT06161025 -
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02376127 -
Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
|
||
| Completed |
NCT02959905 -
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
|
Phase 1 | |
| Recruiting |
NCT04248348 -
Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients
|
||
| Completed |
NCT03890731 -
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
|
Phase 2 |